71 completed, 71 unknown, 52 recruiting, 29 active not recruiting. 119 Phase 2, 94 Phase 1, 21 Not applicable, 16 Phase 3, 5 Early Phase 1.
Follow Diffuse Large B Cell Lymphoma: new trials by email Literature Review of Diffuse Large B Cell Lymphoma trials Research Report on Diffuse Large B Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Tafasitamab, Polatuzumab vedotin, Glofitamab - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | Brown University | 30 | 2026-11-01 | 2026-09-01 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL Epcoritamab, Glofitamab, External Beam Radiation Therapy - Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | University of Utah | 12 | 2026-06-01 | 2026-06-04 |
| Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment Geriatric-guided supportive care, Conventional supportive care - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B | Not applicable | Not yet recruiting | Fondazione Italiana Linfomi - ETS | 170 | 2026-05-01 | 2026-04-15 |
| Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Anti-PD1 armored CD19 CAR-T cells - Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | 30 | 2026-01-01 | 2026-01-28 |
| Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia PointCheck - Diffuse Large B Cell Lymphoma, Multiple Myeloma | Active not recruiting | Leuko Labs, Inc. | 210 | 2025-12-15 | 2026-07-31 | |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-08-06 |
| Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Recruiting | Fondazione Italiana Linfomi - ETS | 200 | 2025-05-05 | 2025-12-29 | |
| IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL Iomab-B, CAR-T cell - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 30 | 2025-04-25 | 2026-05-08 |
| Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma TQB2825 injection +R-CHOP regimen, TQB2825 injection + GemOx - Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 90 | 2025-04-23 | 2026-01-30 |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies Pirtobrutinib, LV20.19 CAR T cells - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2025-02-06 | 2026-08-06 |
| CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant Thiotepa, Carmustine, Autologous Stem Cell Transplant - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Washington University School of Medicine | 36 | 2025-01-16 | 2026-08-28 |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies CLIC-2201 - B-Cell Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | British Columbia Cancer Agency | 24 | 2025-01-02 | 2026-10-14 |
| A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma Cerebral Spinal Fluid ctDNA - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2024-12-11 | 2025-12-18 |
| ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment, De-escalated Treatment - Lymphoma, Lymphoma, B-Cell | Not applicable | Recruiting | Hua-Jay J Cherng, MD | 40 | 2024-12-11 | 2026-01-23 |
| Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy Glofitamab - Diffuse Large B Cell Lymphoma | Phase 2 | Active not recruiting | Samsung Medical Center | 30 | 2024-11-26 | 2025-05-21 |
| Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission Zanubrutinib, Lenalidomide - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 19 | 2024-11-01 | 2024-11-01 |
| Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive selinexor combined with BEAM regimen, BEAM regimen - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 82 | 2024-11-01 | 2024-10-22 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy autologous hematopoietic stem cell - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Ruijin Hospital | 18 | 2024-10-15 | 2024-10-23 |
Showing 20 of 269. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (269) · Lymphoma, Follicular (63) · Lymphoma, Non-Hodgkin (56) · Lymphoma, Mantle-Cell (49) · Lymphoma, B-Cell (40) · Lymphoma, B-Cell, Marginal Zone (35) · Leukemia, Lymphocytic, Chronic, B-Cell (33) · Lymphoma (33) · Recurrence (20) · Burkitt Lymphoma (18) · Neoplasms (16) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Lymphoma, T-Cell, Peripheral (10) · Multiple Myeloma (10) · Hodgkin Disease (9)
Hemic and Lymphatic Diseases (269) · Immune System Diseases (267) · Neoplasms by Histologic Type (267) · Lymphatic Diseases (266) · Immunoproliferative Disorders (265) · Lymphoproliferative Disorders (265) · Neoplasms (253) · Lymphoma (236) · Lymphoma, B-Cell (229) · Lymphoma, Non-Hodgkin (213) · Pathological Conditions, Signs and Symptoms (53) · Pathologic Processes (52) · Disease Attributes (49) · Hematologic Diseases (48) · Leukemia, Lymphoid (40)
Rituximab (48) · Cyclophosphamide (35) · Vincristine (21) · Lenalidomide (18) · Prednisone (18) · Doxorubicin (15) · zanubrutinib (12) · fludarabine (10) · Etoposide (9) · polatuzumab vedotin (9) · Cytarabine (8) · R-CHOP protocol (8) · Gemcitabine (7) · Methotrexate (7) · ibrutinib (7)
Ruijin Hospital (18) · The First Affiliated Hospital with Nanjing Medical University (5) · Masonic Cancer Center, University of Minnesota (4) · Peking Union Medical College Hospital (4) · University Hospital Southampton NHS Foundation Trust (4) · Washington University School of Medicine (4) · Centre Henri Becquerel (3) · Dana-Farber Cancer Institute (3) · Fondazione Italiana Linfomi - ETS (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Herlev Hospital (3) · Institute of Hematology & Blood Diseases Hospital, China (3) · Medical College of Wisconsin (3) · Memorial Sloan Kettering Cancer Center (3) · Mingzhi Zhang (3)
United States (100) · China (77) · France (23) · Italy (19) · United Kingdom (19) · South Korea (16) · Spain (14) · Australia (11) · Canada (8) · Germany (8) · Denmark (6) · Japan (5) · Poland (5) · Taiwan (5) · Brazil (4)
Armin Ghobadi, M.D. (2) · Chen-Lung Lin, MD (2) · Daobin Zhou, MD (2) · Justin Kline, MD (2) · Mats Jerkeman (2) · Matthew Frigault, MD (2) · Nirav Shah, MD (2) · Weili Zhao, PhD (2) · Yanyan Liu, M.D. Ph.D (2) · Adam J Olszewski, MD (1) · Adam Olszewski (1)
PMID 34515338, PMID 34398557, PMID 11807147, PMID 17242396, PMID 17400912, PMID 17785567, PMID 18005385, PMID 21482186, PMID 21940215, PMID 23753028, PMID 25016003, PMID 25415228, PMID 25957999, PMID 27166360, PMID 28356247, PMID 30200906, PMID 30620669, PMID 30952672, PMID 31039052, PMID 31110096, PMID 31350251, PMID 31917843, PMID 31925808, PMID 32076124, PMID 32158186, PMID 32187361, PMID 32888407, PMID 33382529, PMID 33720336, PMID 33904895, PMID 33970454, PMID 34125421, PMID 34222013, PMID 34310745, PMID 34493319, PMID 34495306, PMID 34615723, PMID 34670169, PMID 35136603, PMID 35156195, PMID 35244756, PMID 35332334, PMID 35337365, PMID 35597752, PMID 35610089, PMID 35674661, PMID 36053875, PMID 36102758, PMID 36399518, PMID 36427234
2016 (2), 2023 (2), 2015 (1), 2017 (1), K12CA090433 (1), P01CA111412 (1), P30CA046934 (1), R03CA286676 (1), UL1TR002240 (1)